Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other financing activities (2016 - 2019)

Northwest Biotherapeutics (NWBO) has 9 years of Other financing activities data on record, last reported at $108000.0 in Q4 2019.

  • For Q4 2019, Other financing activities changed N/A year-over-year to $108000.0; the TTM value through Dec 2019 reached $108000.0, down 21.74%, while the annual FY2019 figure was $108000.0, 21.74% down from the prior year.
  • Other financing activities reached $108000.0 in Q4 2019 per NWBO's latest filing, down from $138000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $2.6 million in Q3 2017 and bottomed at -$2.6 million in Q4 2017.
  • Average Other financing activities over 5 years is $110250.0, with a median of $138000.0 recorded in 2015.
  • Peak YoY movement for Other financing activities: plummeted 112.49% in 2015, then skyrocketed 694.39% in 2017.
  • A 5-year view of Other financing activities shows it stood at -$138000.0 in 2015, then skyrocketed by 332.61% to $321000.0 in 2016, then tumbled by 894.39% to -$2.6 million in 2017, then soared by 105.41% to $138000.0 in 2018, then dropped by 21.74% to $108000.0 in 2019.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $108000.0 in Q4 2019, $138000.0 in Q2 2018, and -$2.6 million in Q4 2017.